Myeloablative Chemotherapy

High-dose chemotherapy that kills cells in the bone marrow, including cancer cells. It lowers the number of normal blood-forming cells in the bone… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
PURPOSE Concerns regarding neurocognitive toxicity of whole-brain radiotherapy (WBRT) have motivated development of alternative… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
UNLABELLED PURPOSE We assessed the long-term outcome of patients enrolled on CCG-3891, a high-risk neuroblastoma study in which… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Neuroblastoma, an embryonal tumour of the peripheral sympathetic nervous system, accounts for approximately 15% of all deaths due… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
BACKGROUND Myeloablative megatherapy is commonly used to improve the poor outlook of children with high-risk neuroblastoma, yet… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial.
CONTEXT High-dose chemotherapy poses considerable challenges to emesis management. Although prior studies suggest that… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue.
Four hundred and twenty-nine patients received myeloablative chemotherapy for solid and haematological malignancies in a bone… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
BACKGROUND Children with high-risk neuroblastoma have a poor outcome. In this study, we assessed whether myeloablative therapy in… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors.
PURPOSE To evaluate a strategy that avoids radiotherapy in children less than 6 years of age with newly diagnosed malignant brain… (More)
Is this relevant?
1997
1997
Non-transferrin-bound iron induced by myeloablative chemotherapy.
Previous studies have suggested that non-transferrin-bound plasma iron (NTBI) is present in patients undergoing cytotoxic… (More)
Is this relevant?
Highly Cited
1995
Highly Cited
1995
An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy.
The CD34 antigen is expressed by committed and uncommitted hematopoietic progenitor cells and is increasingly used to assess stem… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?